Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Drops By 28.2%

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 30,600 shares, a drop of 28.2% from the March 31st total of 42,600 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 27,700 shares, the short-interest ratio is presently 1.1 days.

Institutional Investors Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC bought a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned approximately 0.08% of Assembly Biosciences at the end of the most recent reporting period. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Price Performance

Shares of ASMB stock traded down $0.71 during trading hours on Friday, reaching $12.65. The company had a trading volume of 29,550 shares, compared to its average volume of 17,185. The business has a fifty day simple moving average of $13.07 and a 200-day simple moving average of $11.05. Assembly Biosciences has a 12 month low of $7.69 and a 12 month high of $20.04. The company has a market cap of $69.32 million, a price-to-earnings ratio of -0.74 and a beta of 0.57.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a report on Monday, April 1st. StockNews.com upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, April 5th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.